Growth continued in Q2, profitability better but more to be achieved
31/07/20 -"AstraZeneca reported a healthy Q2 growth, outperforming closer peers like Novartis and Roche. This healthy performance was largely driven by oncology (c.45% of group sales). Moreover, the group is a ..."
Pages
63
Language
English
Published on
31/07/20
You may also be interested by these reports :
07/11/25
Genmab’s Q3 results surpassed the street’s expectations, driven by robust performance across most offerings, resulting in solid profitability ...
07/11/25
All segments performed decently in Q3, though the markets were spooked by Hikma’s mid-term outlook downgrade. Operational delays at the Bedford ...
07/11/25
Novonesis delivered a good Q3 2025, with revenue and adjusted EBITDA beating consensus. Organic sales growth of 6% was driven by broad-based volume ...
06/11/25
The Q3 results surpassed expectations, backed by strong performance from Oncology, Respiratory & Immunology, and Rare Disease medicines. Now, the ...